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Abstract –––3-Alkyl-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones were prepared by nitrosative cyclization 
of the appropriate 5,6-diamino-2-phenylpyrimidin-4(3H)-ones with nitrous acid and were subjected to regioselective 
alkylation with several alkylating agents in aprotic solvent at different temperature. Simultaneous 6-N- and 
7-O-alkylations were observed and the regioselectivity varied remarkably with size and shape of the alkylating agents 
as well as with the reaction temperature. Similar N- and O-alkylations as well as selectivity were also observed in the 
case of 2-phenyl-9-propyl-9H-purin-6(1H)-one. Some of the synthesized compounds showed moderate antiviral and 
antitumor activities. 
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1. Introduction 
 
The fused pyrimidine derivatives such as naturally occurring purine bases and their analogues have been focused of 
great interest over many years by reason of their diversified biological activities.1–5 Particular interests are the structural 
modification of purine bases as well as introduction of different functional groups into these bases in the view of 
searching potential antineoplastic and antiviral agents. Introduction of different functional groups, e.g., amino, oxo, 
thioxo, alkylthio, alkyl/aryl groups, into purine bases at different positions has been assessed for potency and selectivity 
for the biological system.2,6–11 6-Chloro, thioxo, alkylthio, amino purine derivatives as well as 9-substituted purine 
derivatives have been reported for good antitumor and antiviral activities.2,6-7,11 A few effective and clinically applicable 
antineoplastic and antiviral agents have been reported so far. Therefore, continuous efforts have been conducted for the 
synthesis of purines and their analogues for searching the effective biological agents. To be biologically active for any 
compound needs some active sites to interact with DNA or RNA. A minor modification of a biologically active 
compound can greatly alter its potentiality. Thus, more modifications of biologically active purine derivatives may lead 
to achieve the highly expected effective antiviral and antitumor drugs. Hence, our laboratory has designed the program 
for the synthesis of fused pyrimidines,12-19 especially purine and modified purine derivatives, by introducing different 
substituents at different positions accompanied the alternation of natural sugar at the 3/9-position with alkyl/aryl groups 
in order to observe the change of antiviral and antitumor activities. Study of regioselective N- and O-alkylations of 
purine and modified purine derivatives is a part of the program since much attention has not been directed toward the 
selective O-alkylation for the synthesis of biologically active compounds in this area. 
We reported19 the synthesis of 1H-, 2H- and 3H-[1,2,3]triazolo[4,5-d]pyrimidine-5,7(4H,6H)-diones and their first 
regioselective 5-O-alkylation along with 4-N-alkylation. There are some reports20–22 of preparation of 6-O-alkyl purine 
derivatives from 6-chloropurines and the conversion of 6-cyanopurines into 6-O-alkyl purine derivatives. Although 
there are many reports of alkylation of xanthine and hypoxanthine, all of them are involved either N-alkylation23–25 or 
S-alkylation.26,27 The interest of most alkylation for xanthines, 8-azaxanthines and 8-azahypoxanthines has been turned 
to the imidazole23,24 and triazole rings.25 In connection with the program of synthesis and regioselective alkylation of 
8-azapurines, we report herein the synthesis of 3-alkyl-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones and 
2-phenyl-9-propyl-9H-purin-6(1H)-one, and their regioselective N- and O-alkylation along with the evaluation of their 
antiviral and antitumor activities. 
 
2. Results and Discussion 
 
2.1. Chemistry 
The requisite key starting materials, 5,6-diamino-2-phenylpyrimidin-4(3H)-ones 1a–g, were prepared from 
6-chloro-2-phenylpyrimidin-4(3H)-one in simple three steps following the standard methods.19,23,28 The nitrosative 
cyclization of these 5,6-diaminopyrimidine derivatives 1a–g with nitrous acid at room temperature led to the formation 
of 3-alkyl-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones 2a–g in 63–86% yields (Scheme 1). The 
methylation of 2a–g with methyl iodide in the presence of anhydrous potassium carbonate in N,N-dimethylformamide 
at room temperature afforded the mixture of 6-N-methylated 3a–g (44–52% yields) and 7-O-methylated derivatives 
4a–g (30–37% yields). The same methylation of 2a–g with methyl iodide at boiling temperature gave the 
6-N-methylated derivatives 3a–g in 71–81% yields, exclusively. The methylation of 2b with methyl iodide in the 
presence of sodium hydride in N,N-dimethylformamide at 0 °C gave 3b and 4b in 52% and 28% yields, respectively.  
 
 
 
The acquit effect of temperature on methylation was examined by carrying out the reaction of 2b with methyl iodide 
at different temperature from 0 to 153 °C as shown in the Figure 1. It was observed that there was no effect of 
temperature between 0 and 100 °C on the ratio of yields, but at over 100 to 153 °C the 6-N-methylation was in 
preference to the 7-O-methylation. Thus, the 6-N-methylated derivative 3b was prevailed exclusively at 153 °C. The 
priority for the formation of the N-methylated derivatives at higher temperature can be explained by the following fact. 
That is to say, an adequate energy is supplied at high temperature to conquer the steric interaction of 5-phenyl group 
with methyl iodide to give the comparatively more stable N-methylated products.29  
 
Figure 1. Relative yields of 6-N-methyl 3b (dotted line) and 7-O-methyl 4b (solid line) isomers yielded by the 
methylation of 2b with MeI at different temperature. 
 
The O-methylation was verified by another synthetic route. Namely, treatment of compounds 2a–d with phosphoryl 
chloride in the presence of N,N-dimethylaniline gave the corresponding 7-chloro derivatives 5a–d in quantitative yields, 
which on subsequent treatment with sodium methoxide in methanol at room temperature yielded the 7-methoxy 
derivatives 4a–d in excellent yields (Scheme 2). The physical and spectral data of 4a–d prepared by the second route 
were quite identical in all respects with the first fraction isolated by column chromatography from a mixture of products 
gained by methylation of 2a–d with methyl iodide at room temperature. The IR, 1H NMR and UV spectra of the O- and 
N-methyl isomers provided satisfactory evidence for their discrimination and identification. Usually IR spectra of the 
7-oxo derivatives 2a–g, 3a–g showed the characteristic absorption band in the region of 1690–1720 cm–1 for C=O 
group. In the case of the O-methylated derivatives, the absorption band based on the 7-C=O in the region of 1690–1720 
cm–1 disappeared. Hence, this evidently revealed the disappearance of the 7-oxo group due to the formation of the 
7-O-methylated derivatives 4a–g. In addition, the 1H NMR spectra displayed considerable confirmation exhibiting 
chemical shifts for 7-O-CH3 protons (δ 4.37–4.40 for compounds 4a–g) in more down field than that of 6-N-CH3 
protons (δ 3.53–3.55 for compounds 3a–g) due to the inductive effect. The UV spectra of these regioiosmers also 
provided the confirmation to assign the 7-O-methylation along with 6-N-methylation. The UV spectra of all O-methyl 
isomers in ethanol exhibited six maxima absorption bands (238, 245–246, 275–276, 284, 293–294 and 304 nm), while 
N-methyl isomers showed two maxima absorption bands (266–267 and 271–272 nm). It is also notable that the physical 
and spectral properties of the 7-O-methyl 4a–g and 7-chloro derivatives 5a–d are about quite analogous due to their 
structural resemblance. Thus, we distinguished and established the 7-O-methylation along with the 6-N-methylation by 
comparing several spectral data. 
 
 
 
Chlorination of 3-(2-hydroxyethyl)- 2f and 3-(3-hydroxypropyl)-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin- 
7(6H)-one 2g was achieved in an analogous way to compounds 2a–d (Scheme 3). Initially, it was expected that the 
chlorination might take place only at the 7-position, but actually, the alcoholic hydroxyl group of both compounds was 
also replaced by a chlorine to afford the corresponding 7-chloro-3-(2-chloroethyl)- 6 and 7-chloro-3-(3-chloropropyl)- 
5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine 7 in 87% and 84% yields, respectively. The absence of the alcoholic 
absorption band in the IR spectra as well as the broad singlet signal attributable to the alcoholic OH proton in the 1H 
NMR spectra of these two derivatives 6 and 7 showed the substitution of hydroxyl group to chlorine. When the 
dichlorinated derivatives 6 and 7 were treated with sodium methoxide in methanol at room temperature, the 
nucleophilic substitution took place only at the 7-position to give the corresponding 3-(2-chloroethyl)-7-methoxy- 8 and 
3-(3-chloropropyl)-7-methoxy-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine 9 in 81% and 88% yields, respectively. 1H 
NMR spectra of these two methoxy derivatives showed only one singlet signal (δ 4.38) attributable to the 7-O-methyl 
protons, which was consistent with the other 7-O-methyl derivatives (δ 4.37-4.40 for 4a–g). Besides, the physical and 
spectral data of 3-(2-hydroxyethyl)-7-methoxy 4f and 3-(3-hydroxypropyl)-7-methoxy-5-phenyl-3H-[1,2,3]triazolo- 
[4,5-d]pyrimidine 4g obtained by methylation of 2f and 2g were different from that of 8 and 9, respectively. Hence, it is 
obvious that the replacement of chlorine by methoxy group took place selectively at the 7-position without at the side 
chain of 6 and 7. 
 
 
 
To examine the effect of size and shape of the alkylating agents on the O- and N-alkylations, compound 2b was 
chosen as the model compound. The alkylation of 2b with dimethyl sulfate, ethyl iodide or benzyl bromide in the 
presence of anhydrous potassium carbonate in N,N-dimethylformamide at room temperature afforded the 7-O-alkylated 
derivatives 4b, 4ba, 4bb as the major products (61–66% yields) along with the 6-N-alkylated derivatives 3b, 3ba, 3bb 
(10–17% yields) (Scheme 4). Even the methylation as well as ethylation of 2b with dimethyl sulfate and ethyl iodide at 
boiling temperature led to the 7-O-methyl 4b (39% yield) and 7-O-ethyl 4ba (41% yield) derivatives as the major 
products accompanied with 6-N-methyl 3b (16% yield) and 6-N-ethyl 3ba (18% yield) derivatives, respectively. In the 
case of benzylation of 2b at boiling temperature two regoisomers 3bb and 4bb were obtained almost in equal quantity. 
Hence, it is apparent that the 7-O-alkylation favored preference over the 6-N-alkylation for bulkier alkylating agents19 
due to the steric interaction of the alkylating agents with the phenyl group at the 5-position. That is, the energy 
produced at boiling temperature in N,N-dimethylformamide is not sufficient enough to overcome the steric interaction 
force for bulkier alkylating agents to give only the more stable 6-N-alkyl derivatives. For confirmation of the 
7-O-alkylation, the compound 4ba was also prepared by treating 5b with sodium ethoxide in ethanol at room 
temperature, which was identical in all respects with the 7-ethoxy derivative obtained by ethylation of 2b. IR, 1H NMR 
and UV spectra as well as microanalyses for these 6-N-alkylated and 7-O-alkylated derivatives were also quite 
satisfactory to assign and differentiate the regioisomers as discussed for 6-N-methyl 3a–g and 7-O-methyl 4a–g 
regioisomers. 
 
 
 
On the other hand, the similar regioselective N- and O-alkylation was also observed in the alkylation on purine ring. 
2-Phenyl-9-propyl-9H-purin-6(1H)-one 10 was prepared by treating free 5,6-diaminopyrimidine derivative 1b with 
85% formic acid in order to observe the alkyaltion position on the pyrimidine ring of it (Scheme 5). The methylation of 
10 with 1 equiv methyl iodide in the presence of anhydrous potassium carbonate in N,N-dimethylformamide at 0 °C 
gave the 1-N-methyl 11a and 6-O-methyl isomer 11b in 26% and 45% yields, respectively. The same methylation with 
excess methyl iodide at room temperature gave 11b and 6,9-dihydro-1,7-dimethyl-6-oxo-2-phenyl-9-propyl-1H-purin- 
7-ium hydroxide 12 in 44% and 30% yields, respectively. Similar methylation of 10 with 1 equiv dimethyl sulfate at 
room temperature gave only 11b in 76% yield. Therefore, it is obvious that the O-methylation of 2-phenylhypoxanthine 
10 takes place more preferentially over the N-methylation compared with that of 2-phenyl-8-axahypoxanthine 2. 
Besides, the 1,9-disubstitted hypoxanthine 11a forms the 1,7,9-trisubstituted quaternary salt 12 with excess alkylating 
agent. The quaternary salt was obtained as hydroxide salt. IR, 1H-NMR and microanalysis data were quite satisfactory 
with the hydroxide salt 12. 
 
  
2.2. Biological activity 
 
2.2.1. Antiviral activity 
Compounds 2a–g, 3a–g,bb , 4a–g,bb, 5a–d, 6 and 8 were evaluated for antiviral activity in vitro against herpes 
simplex virus type 1 (HSV-1) and type 2 (HSV-2) according to the methods developed by Machida et al.30,31 The results 
are summarized in the Table 1. The potency of antiviral activity of each compound is expressed as a minimum 
inhibitory concentration (ED50) required to reduce virus plaque formation by 50% under experimental conditions. 
Among the tested compounds, 5a and 5c were more potential (>0.8 µg/mL) against both viruses. Compound 2e showed 
its activity at the concentration >4 µg/mL. Some compounds, e.g., 2a,d, 3e,bb, 4d, 5b,d, 6, and 8, showed activity 
against both herpes viruses at the concentration >20 µg/mL and some did not exhibit any activity up to 100 µg/mL. 
7-Chloro derivatives are comparatively more active than 6-N-alkyl or 7-O-alkyl derivatives.  
 
2.2.2. Antitumor activity 
The modified32 3-(3,4-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay for cellular growth and 
survival application method developed by Mosmann33 was used to determine the growth inhibitory effects (antitumor 
activity) of the synthesized compounds against CCRF-HSB-2 (human T-cell acute lymphoblastoid leukemia) and KB 
(human oral epidermoid carcinoma) cells in vitro. The results, i.e. 50% inhibitory concentration [IC50 (µg/mL)] of each 
compound against the both cells are summarized in the Table 1. 7-Chloro-5-phenyl-3H-[1,2,3]triazolo[4,5-d]- 
pyrimidines (5b–d, 6, and 8) showed better activity against CCRF-HSB-2 cancer cells (1.9–8.4 µg/mL) than against KB 
cells (8.8–36.4 µg/mL). 3-Octyl-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one 2e showed potential activity 
against CCRF-HSB-2 and KB cells at the concentration 17.5 µg/mL and 11.0 µg/mL, respectively, while 
6-N-methyl-3-octyl derivative 3e exhibited about similar activity (25.9 µg/mL and 29.0 µg/mL) against both cells. Other 
compounds were too low toxic to exhibit potential activity. Thus, it is apparent that the presence of electronegative 
chlorine atom at the 7-position is significant for antitumor activity. Besides, among the alkyl groups at the 9-position, 
octyl group is responsible for increased activity due to its hydrophobic character. 6-N-Alkyl and 7-O-alkyl groups do 
not enhance antitumor activity. 
 
 
 
3. Conclusion 
 
Thus, this can be concluded that the NH proton on the pyrimidine ring of 5-phenyl-3H-[1,2,3]triazolo- 
[4,5-d]pyrimidin-7(6H)-ones and 2-phenyl-9-propyl-9H-purin-6(1H)-one remains as lactam-lactim tautomers. 
Therefore, the N- and O-alkylations (electrophilic substitution) take place simultaneously. The selectivity for the 
alkylation position onto 5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones is highly controllable by temperature 
as well as by the size and shape of the alkylating agents (electrophiles). A few of the synthesized compounds have 
moderate antiviral and antitumor activities. Therefore, this simple and facile methodology for simultaneous N- and 
O-alkylations of lactam-lactim tautomers might be used in future for the preparation of analogous compounds for 
searching potential biological agents. 
 
4. Experimental 
 
4.1. General  
Mps were determined on a Yanagimoto micro-melting point hot stage apparatus and were uncorrected. IR spectra 
were obtained using a JASCO FT/IR-200 spectrophotometer in Nujol mulls. UV spectra were recorded with a Beckman 
DU-68 spectrophotometer in ethanol. IR and UV absorption values in italic refer to wave numbers and wave length 
respectively, at which shoulders or inflexions occur in the absorption. 1H NMR spectra were measured using a VXR 300 
MHz spectrometer and chemical shift values were expressed in δ values (ppm) relative to TMS as an internal standard. 
Coupling constants are given in hertz and signals are quoted as follows: s, signlet; d, doublet; t, triplet; q, quartet; quin, 
quintet; sext, sextet; sept, septed; b, broad; m, multiplet. Microanalyses were measured by a Yanako CHN Corder MT-5 
apparatus. Reaction progress was monitored by analytical thin-layer chromatography (TLC) on pre-coated glass plates 
(silica gel 60 F254 Plate-Merck) and products were visualized by UV light. Column chromatography was accomplished 
on Daisogel IR-60 (63/210 µm, Daiso Co.).  
 
4.2. General procedure for the synthesis of 6-alkylamino-5-amino-2-phenylpyrimidin-4(3H)-one hemisulfates 
(1a–g) 
A mixture of an appropriate 6-alkylamino-5-nitroso-2-phenylpyrimidin-4(3H)-ones (8.0 mmol), acetic acid (5 mL), 
water (50 mL), and methanol (50 mL) was heated to ca. 60 °C and to it was added Na2S2O4 (25–32 mmol) by portions 
with stirring. Then, the mixture was heated at 70 °C for 0.5–1.0 h. After the reaction was complete, the solution was 
concentrated to ca. 20 mL and to it was added water (25 mL). Upon keeping the mixture at room temperature (rt) for 
several hours, the solid deposited was collected by filtration to give the corresponding 5,6-diamino hemisulfate 
derivatives 1a–g as pale yellow powdery crystals. For analysis a portion of these products were recrystallized from 
dilute H2SO4 except 1e, which was recrystallized from a mixture of ethanol and dilute H2SO4. 
 
4.2.1. 5-Amino-6-ethylamino-2-phenylpyrimidin-4(3H)-one hemisulfate (1a)  
Yield 1.28 g (5.52 mmol, 69%); mp 217–218 °C (decomp.); Rf 0.26 (n-hexane/EtOAc, 1:3); IR (Nujol): 3345, 3070 
(NH), 1635 (C=O) cm–1; 1H NMR (CDCl3): δ 1.21 (t, J=7.2 Hz, 3H, CH3), 3.49 (br s, 2H, CH2), 6.40 (br s, 1H, 6-NH), 
7.43–7.52 (m, 3H, Ph-m,pH), 8.03–8.13 (m, 2H, Ph-oH); Anal. Calcd for C12H14N4O·(1/2H2SO4 + 2/3H2O): C 49.47, H 
5.65, N 19.23. Found: C 49.53, H 5.44, N 19.23.   
 
4.2.2. 5-Amino-2-phenyl-6-propylaminopyrimidin-4(3H)-one hemisulfate (1b) 
Yield 1.58 g (6.48 mmol, 81%); mp 215–216 °C (decomp.); Rf 0.29 (n-hexane/EtOAc, 1:3); IR (Nujol): 3340, 3065 
(NH), 1640 (C=O) cm–1; 1H NMR (CDCl3): δ 0.96 (t, J=7.5 Hz, 3H, CH3), 1.57–1.66 (m, 2H, N-CH2CH2), 3.44 (br s, 
2H, N-CH2), 6.38 (br s, 1H, 6-NH), 7.41–7.53 (m, 3H, Ph-m,pH), 8.02–8.14 (m, 2H, Ph-oH); Anal. Calcd for 
C13H16N4O·(1/2H2SO4 + 1/2H2O): C 51.64, H 6.00, N 18.53. Found: C 51.67, H 5.87, N 18.38.   
 
4.2.3. 5-Amino-6-isopropylamino-2-phenylpyrimidin-4(3H)-one hemisulfate (1c) 
Yield 1.51 g (6.16 mmol, 77%); mp 208–210 °C (decomp.); Rf 0.29 (n-hexane/EtOAc, 1:3); IR (Nujol): 3270, 3060 
(NH), 1655 (C=O) cm–1; 1H NMR (CDCl3): δ 1.23 (d, J=6.3 Hz, 6H, 2×CH3), 4.24–4.41 (m, 1H, CH), 6.18 (br s, 1H, 
6-NH), 7.49–7.64 (m, 3H, Ph-m,pH), 8.05–8.14 (m, 2H, Ph-oH); Anal. Calcd for C13H16N4O·(1/2H2SO4 + 1/4H2O): C 
52.42, H 5.92, N 18.81. Found: C 52.60, H 5.90, N 18.44.   
 
4.2.4. 5-Amino-6-isobutylamino-2-phenylpyrimidin-4(3H)-one hemisulfate (1d) 
Yield 1.61 g (6.24 mmol, 78%); mp 205–206 °C (decomp.); Rf 0.31 (n-hexane/EtOAc, 1:3); IR (Nujol): 3280, 3070 
(NH), 1630 (C=O) cm–1; 1H NMR (CDCl3): δ 0.94 (d, J=6.6 Hz, 6H, 2×CH3), 1.83–1.96 (m, 1H, N-CH2CH), 3.30 (s, 
2H, N-CH2), 6.31 (br s, 1H, 6-NH), 7.43–7.52 (m, 3H, Ph-m,pH), 8.12–8.21 (m, 2H, Ph-oH); Anal. Calcd for 
C14H18N4O·1/2H2SO4: C 54.71, H 6.23, N 18.23. Found: C 55.07, H 6.18, N 18.58.  
 
4.2.5. 5-Amino-6-octylamino-2-phenylpyrimidin-4(3H)-one hemisulfate (1e) 
Yield 1.91 g (6.08 mmol, 76%); mp 158–159 °C (decomp.); Rf 0.49 (n-hexane/EtOAc, 1:3); IR (nujol): 3345, 3070 
(NH), 1635 (C=O) cm–1; 1H NMR (CDCl3): δ 0.85 (s, 3H, CH3), 1.25 (br s, 10H, [CH2]5CH3), 1.50–1.66 (m, 2H, 
N-CH2CH2), 3.45 (br s, 2H, N-CH2), 6.16 (br s, 1H, 6-NH), 7.40–7.52 (m, 3H, Ph-m,pH), 8.01–8.13 (m, 2H, Ph-oH); 
Anal. Calcd for C18H26N4O·1/2H2SO4: C 59.48, H 7.49, N 15.41. Found: C 59.87, H 7.39, N 15.45.   
 
4.2.6. 5-Amino-6-(2-hydroxyethylamino)-2-phenylpyrimidin-4(3H)-one hemisulfate (1f) 
Yield 1.64 g (6.64 mmol, 83%); mp 215–216 °C (decomp.); Rf 0.45 (EtOAc/EtOH, 4:1); IR (Nujol): 3320 (OH), 
3200 (NH), 1640 (C=O) cm–1; 1H NMR (CDCl3): δ 3.44 (q, J=6.9 Hz, 2H, O-CH2), 3.57 (br s, 2H, N-CH2), 4.29 (br s, 
1H, OH), 5.97 (br s, 1H, 6-NH), 7.38–7.45 (m, 3H, Ph-m,pH), 8.00–8.13 (m, 2H, Ph-oH); Anal. Calcd for 
C12H14N4O2·(1/2H2SO4 + 1/8H2O): C 48.44, H 5.17, N 18.83. Found: C 48.37, H 5.37, N 18.59.  
 
4.2.7. 5-Amino-6-(3-hydroxypropylamino)-2-phenylpyrimidin-4(3H)-one hemisulfate (1g) 
Yield 1.56 g (6.0 mmol, 75%); mp 210–211 °C (decomp.); Rf 0.47 (EtOAc/EtOH, 4:1); IR (Nujol): 3310 (OH), 
3200 (NH), 1640 (C=O) cm–1; 1H NMR (CDCl3): δ 1.73 (quin, J=6.6 Hz, 2H, N-CH2CH2), 3.44 (q, J=6.9 Hz, 2H, 
O-CH2), 3.51 (t, J=5.7 Hz, 2H, N-CH2), 4.18 (br s, 1H, OH), 6.27 (br s, 1H, 6-NH), 7.40–7.54 (m, 3H, Ph-m,pH), 
8.01–8.13 (m, 2H, Ph-oH); Anal. Calcd for C13H16N4O2·1/2H2SO4: C 50.48, H 5.54, N 18.11. Found: C 50.54, H 5.62, 
N 17.91.  
 
4.3. General procedure for the synthesis of 3-alkyl-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-ones (2a–g) 
A cooled solution of NaNO2 (10.0 mmol) in water (5 mL) on ice was added to a solution of an appropriate 1a–g 
(6.0 mmol) in 10% HCl (20 mL) at 0–5 °C with stirring over 20 min. Then, the reaction solution was brought to rt and 
stirred for 3–5 h. The solid deposited was collected by filtration, washed with water and dried to afford the 
corresponding [1,2,3]triazolo derivatives 2a–g. 
 
4.3.1. 3-Ethyl-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one (2a) 
Pale yellow powdery crystals; yield 1.25 g (5.16 mmol, 86%); mp 257–258 °C (EtOAc); Rf 0.38 (n-hexane/EtOAc, 
1:2); IR (Nujol): 3180 (NH), 1695 (CO) cm–1; 1H NMR (CDCl3): δ 1.67 (t, J=7.2 Hz, 3H, CH3), 4.66 (q, J=7.2 Hz, 2H, 
CH2), 7.51–7.60 (m, 3H, Ph-m,pH), 8.21 (dd, Jo,p=2.1 Hz, Jo,m=7.8 Hz, 2H, Ph-oH), 12.36 (br s, 1H, NH); UV (EtOH): 
λmax (log ε) 238 (4.44), 268 (4.35), 274 (4.37), 283 nm (4.36); Anal. Calcd for C12H11N5O: C, 59.74; H, 4.60; N, 29.03. 
Found: C, 59.60; H, 4.56; N, 28.83. 
 
4.3.2. 5-Phenyl-3-propyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one (2b) 
Pale yellow needles; yield 1.26 g (4.92 mmol, 82%); mp 206–207 °C (EtOAc); Rf 0.41 (n-hexane/EtOAc, 1:2); IR 
(Nujol): 3180 (NH), 1700 (CO) cm–1; 1H NMR (CDCl3): δ 1.03 (t, J=7.5 Hz, 3H, CH3), 2.10 (m, 2H, N-CH2CH2), 4.60 
(t, J=7.2 Hz, 2H, N-CH2), 7.61–7.63 (m, 3H, Ph-m,pH), 8.29 (dd, Jo,p=2.4 Hz, Jo,m=7.5 Hz, 2H, Ph-oH), 12.04 (s, 1H, 
NH); UV (EtOH): λmax (log ε) 238 (4.43), 268 (4.34), 274 (4.36), 284 nm (4.34); Anal. Calcd for C13H13N5O: C, 61.16; 
H, 5.13; N, 27.43. Found: C, 61.28; H, 5.28; N, 27.11.  
 
4.3.3. 3-Isopropyl-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one (2c) 
Pale yellow powdery crystals; yield 1.20 g (4.68 mmol, 78%); mp 261–262 °C (EtOAc); Rf 0.42 (n-hexane/EtOAc, 
1:2); IR (Nujol): 3180 (NH), 1690 (CO) cm–1; 1H NMR (CDCl3): δ 1.75 (d, J=7.2 Hz, 6H, 2×CH3), 5.20 (sept, J=7.2 
Hz, 1H, CH), 7.52–7.61 (m, 3H, Ph-m,pH), 8.21 (dd, Jo,p=2.4 Hz, Jo,m=7.5 Hz, 2H, Ph-oH), 12.12 (s, 1H, NH); UV 
(EtOH): λmax (log ε) 237 (4.4), 268 (4.31), 275 (4.34), 284 nm (4.34); Anal. Calcd for C13H13N5O: C, 61.16; H, 5.13; N, 
27.43. Found: C, 61.48; H, 5.19; N, 27.51. 
 
4.3.4. 3-Isobutyl-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one (2d) 
Pale yellow prisms; yield 1.39 g (5.16 mmol, 86%); mp 203–204 °C (EtOAc); Rf 0.45 (n-hexane/EtOAc, 1:2); IR 
(Nujol): 3170 (NH), 1700 (CO) cm–1; 1H NMR (CDCl3): δ 1.02 (d, J=6.9 Hz, 6H, 2×CH3), 2.40–2.53 (m, 1H, 
N-CH2CH), 4.45 (d, J=7.2 Hz, 2H, N-CH2), 7.58–7.65 (m, 3H, Ph-m,pH), 8.26 (dd, Jo,p=2.4 Hz, Jo,m=7.2 Hz, 2H, 
Ph-oH), 11.79 (s, 1H, NH); UV (EtOH): λmax (log ε) 237 (4.47), 268 (4.38), 275 (4.40), 284 nm (4.39); Anal. Calcd for 
C14H15N5O: C, 62.44; H, 5.61; N, 26.01. Found: C, 62.62; H, 5.66; N, 26.04. 
 
4.3.5. 3-Octyl-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one (2e) 
Colorless powdery crystals; yield 1.51 g (4.62 mmol, 77%); mp 132–133 °C (n-hexane/EtOAc); Rf 0.53 
(n-hexane/EtOAc, 1:2); IR (Nujol): 3190 (NH),1690 (CO) cm–1; 1H NMR (CDCl3): δ 0.86 (t, J=7.2 Hz, 3H, CH3), 1.26 
(br s, 6H, CH2[CH2]3CH3), 1.38 (br s, 4H, N-CH2CH2[CH2]2), 2.03–2.23 (m, 2H, N-CH2CH2), 4.63 (t, J=7.52 Hz, 2H, 
N-CH2), 7.61–7.65 (m, 3H, Ph-m,pH), 8.25 (dd, Jo,p=2.1 Hz, Jo,m=7.5 Hz, 2H, Ph-oH), 11.55 (s, 1H, NH); UV (EtOH): 
λmax (log ε) 238 (4.44), 268 (4.36), 273 (4.36), 284 nm (4.34); Anal. Calcd for C18H23N5O: C, 66.44; H, 7.12; N, 21.52. 
Found: C, 66.52; H, 7.21; N, 21.42. 
 
4.3.6. 3-(2-Hydroxyethyl)-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one (2f) 
Colorless powdery crystals; yield 1.16 g (4.50 mmol, 75%); mp 270–271 °C (EtOAc/EtOH); Rf 0.43 (EtOAc); IR 
(Nujol): 3360 (OH), 3185 (NH), 1715 (CO) cm–1; 1H NMR (DMSO-d6): δ 3.94 (q, J=5.7 Hz, 2H, O-CH2), 4.61 (t, 
J=5.7 Hz, 2H, N-CH2), 4.98 (t, J=5.7 Hz, 1H, OH), 7.54–7.63 (m, 3H, Ph-m,pH), 8.15 (d, J=7.5 Hz, 2H, Ph-oH), 12.77 
(s, 1H, NH); UV (EtOH): λmax (log ε) 237 (4.46), 268 (4.37), 274 (4.39), 283 nm (4.38); Anal. Calcd for C12H11N5O2: C, 
56.03; H, 4.31; N, 27.22. Found: C, 56.09; H, 4.38; N, 27.42. 
 
4.3.7. 3-(3-Hydroxypropyl)-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one (2g) 
Colorless prisms; yield 1.03 g (3.78 mmol, 63%); mp 193–194 °C (EtOAc); Rf 0.42 (EtOAc); IR (Nujol): 3375 
(OH), 3180 (NH), 1700 (CO) cm–1; 1H NMR (CDCl3): δ 2.25 (quin, J=6.3 Hz, 2H, N-CH2CH2), 2.66 (br s, 1H, OH), 
3.66 (t, J=6.0 Hz, 2H, O-CH2), 4.76 (t, J=6.9 Hz, 2H, N-CH2), 7.50–7.59 (m, 3H, Ph-m,pH), 8.18 (dd, Jo,p=1.5 Hz, 
Jo,m=7.8 Hz, 2H, Ph-oH), 12.41 (s, 1H, NH); UV (EtOH): λmax (log ε) 237 (4.38), 268 (4.29), 273 (4.31), 284 nm(4.32); 
Anal. Calcd for C13H13N5O2: C, 57.56; H, 4.83; N, 25.82. Found: C, 57.63; H, 4.96; N, 25.55. 
 
4.4. General procedure for the methylation of 2a–g with methyl iodide  
4.4.1. At room temperature (A) 
A mixture of an appropriate 2a–g (2.5 mmol), anhydrous K2CO3 (5.0 mmol) and MeI (7.5 mmol) in dry DMF (25 
mL) was stirred at rt for 5-6 h. Then, the solution was evaporated to dryness in vacuo and water (15 mL) was added to 
the residue. The solid deposited was collected by filtration and washed with water. The two regioisomers cropped were 
separated by column chromatography on silica gel using an appropriate mixture of n-hexane and EtOAc as eluting 
solvent to afford the corresponding 7-methoxy 4a–g and 6-methyl derivatives 3a–g as the first and second fraction, 
respectively. 
 
4.4.1.1. 3-Ethyl-6-methyl-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one (3a) 
Colorless needles; yield 0.31 g (1.23 mmol, 49%); mp 221–222 °C (n-hexane/EtOAc); Rf 0.43 (n-hexane/EtOAc, 
1:2); IR (Nujol): 1720 (CO) cm–1; 1H NMR (CDCl3): δ 1.62 (t, J=7.2 Hz, 3H, CH2CH3), 3.53 (s, 3H, N-CH3), 4.60 (q, 
J=7.2 Hz, 2H, CH2), 7.53–7.59 (m, 5H, Ph-H); UV (EtOH): λmax (log ε) 267 (4.29), 272 nm (4.28); Anal. Calcd for 
C13H13N5O: C, 61.16; H, 5.13; N, 27.43. Found: C, 60.91; H, 4.98; N, 27.26. 
 
4.4.1.2. 6-Methyl-5-phenyl-3-propyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one (3b) 
Pale yellow prisms; yield 0.34 g (1.28 mmol, 51%); mp 170–171 °C (n-hexane/EtOAc); Rf 0.49 (n-hexane/EtOAc, 
1:2); IR (Nujol): 1715 (CO) cm–1; 1H NMR (CDCl3): δ 0.99 (t, J=7.5 Hz, 3H, CH2CH3), 2.04 (sext, J=7.5 Hz, 2H, 
N-CH2CH2), 3.53 (s, 3H, N-CH3), 4.50 (t, J=7.8 Hz, 2H, N-CH2), 7.52–7.57 (m, 5H, Ph-H); UV (EtOH): λmax (log ε) 
267 (4.41), 272 nm (4.39 ); Anal. Calcd for C14H15N5O: C, 62.44; H, 5.61; N, 26.01. Found: C, 62.13; H, 5.60; N, 
26.02. 
 
4.4.1.3. 3-Isopropyl-6-methyl-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one (3c) 
Colorless prisms; yield 0.30 g (1.10 mmol, 44%); mp 200–201 °C (n-hexane/EtOAc); Rf 0.51 (n-hexane/EtOAc, 
1:2); IR (Nujol): 1720 (CO) cm–1; 1H NMR (CDCl3): δ 1.69 (d, J=6.6 Hz, 6H, CH3CHCH3), 3.53 (s, 3H, N-CH3), 5.11 
(sept, J=6.6 Hz, 1H, CH), 7.53–7.59 (m, 5H, Ph-H); UV (EtOH): λmax (log ε) 266 (4.33), 272 nm (4.32); Anal. Calcd 
for C14H15N5O: C, 62.44; H, 5.61; N, 26.01. Found: C, 62.35; H, 5.62; N, 25.87. 
 
4.4.1.4. 3-Isobutyl-6-methyl-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one (3d) 
Colorless needles; yield 0.35 g (1.23 mmol, 49%); mp 159–160 °C (n-hexane/EtOAc); Rf 0.52 (n-hexane/EtOAc, 
1:2); IR (Nujol): 1720 (CO) cm–1; 1H NMR (CDCl3): δ 0.97 (d, J=6.6 Hz, 6H, CH3CHCH3), 2.34–2.48 (m, 1H, 
N-CH2CH), 3.54 (s, 3H, N-CH3), 4.35 (d, J=7.2 Hz, 2H, N-CH2), 7.52–7.59 (m, 5H, Ph-H); UV (EtOH): λmax (log ε) 
267 (4.38), 272 nm (4.37); Anal. Calcd for C15H17N5O: C, 63.59; H, 6.05; N, 24.72. Found: C, 63.69; H, 6.09; N, 24.48. 
 
4.4.1.5. 6-Methyl-3-octyl-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one (3e) 
Colorless powdery crystals; yield 0.38 g (1.13 mmol, 45%); mp 102–103 °C (n-octane/EtOAc); Rf 0.60 
(n-hexane/EtOAc, 1:2); IR (Nujol): 1720 (CO) cm–1; 1H NMR (CDCl3): δ 0.86 (t, J=6.9 Hz, 3H, CH2CH3), 1.24 (br s, 
6H, CH2[CH2]3CH3), 1.34 (br s, 4H, N-CH2CH2[CH2]2), 1.94–2.04 (m, 2H, N-CH2CH2), 3.53 (s, 3H, N-CH3), 4.52 (t, 
J=7.5 Hz, 2H, N-CH2), 7.52–7.57 (m, 5H, Ph-H); UV (EtOH): λmax (log ε) 266 (4.32), 271 nm (4.30); Anal. Calcd for 
C19H25N5O: C, 67.23; H, 7.42; N, 20.63. Found: C, 67.57; H, 7.53; N, 20.43. 
 
4.4.1.6. 3-(2-Hydroxyethyl)-6-methyl-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one (3f) 
Colorless powdery crystals; yield 0.35 g (1.30 mmol, 52%); mp 212–213 °C (EtOAc); Rf 0.50 (EtOAc); IR (Nujol): 
3440 (OH), 1695 (CO) cm–1; 1H NMR (CDCl3): δ 3.35 (t, J=6.6 Hz, 1H, OH), 3.54 (s, 3H, N-CH3), 4.17 (q, J=6.0 Hz, 
2H, O-CH2), 4.72 (t, J=5.1 Hz, 2H, N-CH2), 7.54–7.59 (m, 5H, Ph-H); UV (EtOH): λmax (log ε) 267 (4.38), 271 nm 
(4.37); Anal. Calcd for C13H13N5O2: C, 57.56; H, 4.83; N, 25.82. Found: C, 57.85; H, 4.80; N, 26.20. 
 
4.4.1.7. 3-(3-Hydroxypropyl)-6-methyl-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one (3g) 
Pale yellow powdery crystals; yield 0.34 g (1.20 mmol, 48%); mp 146–147 °C (n-hexane/EtOAc); Rf 0.49 (EtOAc); 
IR (Nujol): 3395 (OH), 1705 (CO) cm–1; 1H NMR (CDCl3): 2.17 (quin, J=6.0 Hz, 2H, N-CH2CH2), 2.73 (br s, 1H, OH), 
3.55 (s, 3H, N-CH3), 3.61 (br s, 2H, O-CH2), 4.73 (t, J=6.3 Hz, 2H, N-CH2), 7.53–7.59 (m, 5H, Ph-H); UV (EtOH): 
λmax (log ε) 267 (4.33), 271 nm (4.31); Anal. Calcd for C14H15N5O2: C, 58.94; H, 5.30; N, 24.55. Found: C, 58.79; H, 
5.29; N, 24.24. 
 
4.4.1.8. 3-Ethyl-7-methoxy-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (4a) 
Colorless needles; yield 0.23 g (0.90 mmol, 36%); mp 135–136 °C (n-octane/EtOAc); Rf 0.32 (n-hexane/EtOAc, 
5:1); IR (Nujol): 1250, 1080 (C-O-C) cm–1; 1H NMR (CDCl3): δ 1.72 (t, J=7.2 Hz, 3H, CH2CH3), 4.37 (s, 3H, O-CH3), 
4.76 (q, J=7.2 Hz, 2H, N-CH2), 7.47–7.51 (m, 3H, Ph-m,pH), 8.53 (dd, Jo,p=2.1 Hz, Jo,m=7.8 Hz, 2H, Ph-oH); UV 
(EtOH): λmax (log ε) 238 (4.66), 245 (4.62), 276 (4.63), 284 (4.65), 294 (4.60), 304 nm (4.36); Anal. Calcd for 
C13H13N5O: C, 61.16; H, 5.13; N, 27.43. Found: C, 61.12; H, 5.20; N, 27.21. 
 
4.4.1.9. 7-Methoxy-5-phenyl-3-propyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (4b) 
Colorless needles; yield 0.22 g (0.80 mmol, 32%); mp 119–120 °C (n-octane/EtOAc); Rf 0.35 (n-hexane/EtOAc, 
5:1); IR (Nujol): 1245, 1080 (C-O-C) cm–1; 1H NMR (CDCl3): δ 1.02 (t, J=7.2 Hz, 3H, CH2CH3), 2.13 (sext, J=7.2 Hz, 
2H, N-CH2CH2), 4.38 (s, 3H, O-CH3), 4.68 (t, J=7.2 Hz, 2H, N-CH2), 7.48–7.52 (m, 3H, Ph-m,pH), 8.55 (dd, Jo,p=2.4 
Hz, Jo,m=7.5 Hz, 2H, Ph-oH); UV (EtOH): λmax (log ε) 238 (4.61), 245 (4.58), 276 (4.57), 284 (4.58), 293 (4.54), 304 
nm (4.31); Anal. Calcd for C14H15N5O: C, 62.44; H, 5.61; N, 26.01. Found: C, 62.28; H, 5.62; N, 25.94. 
 
4.4.1.10. 3-Isopropyl-7-methoxy-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (4c) 
Colorless needles; yield 0.23 g (0.85 mmol, 34%); mp 139–140 °C (n-octane/EtOAc); Rf 0.37 (n-hexane/EtOAc, 
5:1); IR (Nujol): 1245, 1065 (C-O-C) cm–1; 1H NMR (CDCl3): δ 1.80 (d, J=6.9 Hz, 6H, CH3CHCH3), 4.37 (s, 3H, 
O-CH3), 5.32 (sept, J=6.9 Hz, 1H, CH), 7.50–7.52 (m, 3H, Ph-m,pH), 8.55 (dd, Jo,p=2.1 Hz, Jo,m=7.8 Hz, 2H, Ph-oH); 
UV (EtOH): λmax (log ε) 238 (4.62), 245 (4.58), 276 (4.58), 284 (4.61), 293 (4.57), 304 nm (4.32); Anal. Calcd for 
C14H15N5O: C, 62.44; H, 5.61; N, 26.01. Found: C, 62.13; H, 5.48; N, 25.96. 
 
4.4.1.11. 3-Isobutyl-7-methoxy-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (4d) 
Pale yellow plates; yield 0.26 g (0.93 mmol, 37%); mp 104–105 °C (n-octane/EtOAc); Rf 0.40 (n-hexane/EtOAc, 
5:1); IR (Nujol): 1245, 1085 (C-O-C) cm–1; 1H NMR (CDCl3): δ 1.02 (d, J=6.6 Hz, 6H, CH3CHCH3), 2.47–2.59 (m, 1H, 
N-CH2CH), 4.38 (s, 3H, O-CH3), 4.52 (d, J=7.2 Hz, 2H, N-CH2), 7.49–7.54 (m, 3H, Ph-m,pH), 8.56 (dd, Jo,p=2.1 Hz, 
Jo,m=7.5 Hz, 2H, Ph-oH); UV (EtOH): λmax (log ε) 238 (4.60), 246 (4.57), 276 (4.58), 284 (4.60), 293 (4.56), 304 nm 
(4.32); Anal. Calcd for C15H17N5O: C, 63.59; H, 6.05; N, 24.72. Found: C, 63.56; H, 6.08; N, 24.75. 
 
4.4.1.12. 7-Methoxy-3-octyl-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (4e) 
Pale yellow powdery crystals; yield 0.26 g (0.75 mmol, 30%); mp 58–59 °C (n-octane); Rf 0.47 (n-hexane/EtOAc, 
5:1); IR (Nujol): 1245, 1080 (C-O-C) cm–1; 1H NMR (CDCl3): δ 0.86 (t, J=6.9 Hz, 3H, CH2CH3), 1.25 (br s, 6H, 
CH2[CH2]3CH3), 1.38 (br s, 4H, N-CH2CH2[CH2]2), 2.05–2.13 (m, 2H, N-CH2CH2), 4.38 (s, 3H, O-CH3), 4.70 (t, J=7.2 
Hz, 2H, N-CH2), 7.49–7.52 (m, 3H, Ph-m,pH), 8.55 (dd, Jo,p=1.8 Hz, Jo,m=7.5 Hz, 2H, Ph-oH); UV (EtOH): λmax (log ε) 
238 (4.55), 246 (4.52), 275 (4.50), 284 (4.51), 293 (4.47), 304 nm (4.25); Anal. Calcd for C19H25N5O: C, 67.23; H, 7.42; 
N, 20.63. Found: C, 66.98; H, 7.22; N, 20.85. 
 
4.4.1.13. 3-(2-Hydroxyethyl)-7-methoxy-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (4f) 
Colorless needles; yield 0.24 g (0.88 mmol, 35%); mp 163–164 °C (n-hexane/EtOAc); Rf 0.39 (n-hexane/EtOAc, 
1:2); IR (Nujol): 3360 (OH), 1250, 1060 (C-O-C) cm–1; 1H NMR (CDCl3): 4.08 (t, J=6.6 Hz, 1H, OH), 4.28 (q, J=6.6 
Hz, 2H, O-CH2), 4.37 (s, 3H, O-CH3), 4.90 (t, J=4.8 Hz, 2H, N-CH2), 7.49–7.55 (m, 3H, Ph-m,pH), 8.49 (dd, Jo,p=2.1 
Hz, Jo,m=7.5 Hz, 2H, Ph-oH); UV (EtOH): λmax (log ε) 238 (4.70), 245 (4.67), 276 (4.67), 284 (4.69), 293 (4.65), 304 
nm (4.41); Anal. Calcd for C13H13N5O2: C, 57.56; H, 4.83; N, 25.82. Found: C, 57.66; H, 4.75; N, 26.11. 
 
4.4.1.14. 3-(3-Hydroxypropyl)-7-methoxy-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (4g) 
Colorless needles; yield 0.21 g (0.75 mmol, 30%); mp 138–139 °C (n-octane/EtOAc); Rf 0.36 (n-hexane/EtOAc, 
1:2); IR (Nujol): 3355 (OH), 1245, 1050 (C-O-C) cm–1; 1H NMR (CDCl3): 2.24 (quin, J=6.3 Hz, 2H, N-CH2CH2), 3.17 
(br s, 1H, OH), 3.59 (t, J=5.7 Hz, 2H, O-CH2), 4.40 (s, 3H, O-CH3), 4.91 (t, J=6.3 Hz, 2H, N-CH2), 7.48–7.53 (m, 3H, 
Ph-m,pH), 8.48 (dd, Jo,p=1.8 Hz, Jo,m=7.8 Hz, 2H, Ph-oH); UV (EtOH): λmax (log ε) 238 (4.54), 246 (4.50), 276 (4.49), 
284 (4.49), 294 (4.45), 304 nm (4.23); Anal. Calcd for C14H15N5O2: C, 58.94; H, 5.30; N, 24.55. Found: C, 58.66; H, 
5.29; N, 24.65. 
 
4.4.2. At boiling temperature (B) 
A mixture of an appropriate 2a–g (1.8 mmol), anhydrous K2CO3 (3.6 mmol) and MeI (7.2 mmol) in dry DMF (20 
mL) was refluxed for 1 h. Then, the solution was evaporated to dryness in vacuo and water (12 mL) was added to the 
residue. The solid deposited was filtered, washed with water, and recrystallized from an appropriate organic solvent to 
give the corresponding 6-N-methyl derivatives 3a–g in 81%, 76%, 73%, 81%, 71%, 76% and 74% yields, respectively. 
 
4.5. Methylation of 2b with methyl iodide in the presence of NaH 
A mixture of 2b (0.4 g, 1.57 mmol), NaH (0.12 g, 5.0 mmol), and MeI (0.61 g, 4.3 mmol) in dry DMF (25 mL) was 
stirred at 0 °C for 7 h. After the usual work-up like above general method as described in Section 4.4.1., the compounds 
3b and 4b were obtained in 52% and 28% yields, respectively.  
 
4.6. General procedure for the chlorination of 2a–d 
To a cooled mixture of an appropriate 2a–d (3.0 mmol) and phosphoryl chloride (POCl3) (12 mL) was added 
N,N-dimethylaniline (0.7 mL) with stirring and the reaction mixture was refluxed gently for 3 h. Then, the excess POCl3 
was evaporated in vacuo and the residue was treated with cracked ice (20 g). Thus, the solid deposited was filtered, 
washed well with water and dried to give the corresponding 7-chloro- derivatives 5a–d.  
 
4.6.1. 7-Chloro-3-ethyl-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (5a) 
Pale yellow powdery crystals; yield 0.65 g (2.52 mmol, 84%); mp 116–117 °C (n-hexane); Rf 0.41 (n-hexane/EtOAc, 
5:1); IR (Nujol): 1590, 1560, 1460, 1400, 1155, 705 cm–1; 1H NMR (CDCl3): δ 1.74 (t, J=7.2 Hz, 3H, CH3), 4.85 (q, 
J=7.2 Hz, 2H, CH2), 7.50–7.55 (m, 3H, Ph-m,pH), 8.56 (dd, Jo,p=2.4 Hz, Jo,m=8.1 Hz, 2H, Ph-oH); UV (EtOH): λmax 
(log ε) 246 (4.68), 252 (4.66), 265 (4.42), 273 (4.41), 289 (4.44), 302 nm (4.48); Anal. Calcd for C12H10ClN5: C, 55.50; 
H, 3.88; N, 26.97. Found: C, 55.71; H, 4.01; N, 26.79. 
 
4.6.2. 7-Chloro-5-phenyl-3-propyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (5b) 
Pale yellow needles; yield 0.76 g (2.79 mmol, 93%); mp 98–99 °C (n-hexane); Rf 0.51 (n-hexane/EtOAc, 5:1); IR 
(Nujol): 1590, 1555, 1465, 1400, 1160, 710 cm–1; 1H NMR (CDCl3): δ 1.04 (t, J=7.5 Hz, 3H, CH2CH3), 2.16 (sext, 
J=7.5 Hz, 2H, N-CH2CH2), 4.73 (t, J=7.5 Hz, 2H, N-CH2), 7.52–7.56 (m, 3H, Ph-m,pH), 8.56 (dd, Jo,p=1.8 Hz, Jo,m=8.1 
Hz, 2H, Ph-oH); UV (EtOH): λmax (log ε) 247 (4.61), 253 (4.60), 265 (4.38), 272 (4.36), 290 (4.37), 302 nm (4.39); 
Anal. Calcd for C13H12ClN5: C, 57.04; H, 4.42; N, 25.59. Found: C, 56.82; H, 4.39; N, 25.61. 
 
4.6.3. 7-Chloro-3-isopropyl-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (5c) 
Colorless needles; yield 0.71 g (2.61 mmol, 87%); mp 118–119 °C (n-hexane); Rf 0.52 (n-hexane/EtOAc, 5:1); IR 
(Nujol): 1590, 1560, 1460, 1380, 1160, 710 cm–1; 1H NMR (CDCl3): δ 1.83 (d, J=6.6 Hz, 6H, 2×CH3), 5.36 (sept, 
J=6.6 Hz, 1H, CH), 7.48–7.53 (m, 3H, Ph-m,pH), 8.55 (dd, Jo,p= 2.4 Hz, Jo,m=7.8 Hz, 2H, Ph-oH); UV (EtOH): λmax 
(log ε) 247 (4.56), 252 (4.55), 265 (4.33), 272 (4.31), 290 (4.31), 301 nm (4.36); Anal. Calcd for C13H12ClN5: C, 57.04; 
H, 4.42; N, 25.59. Found: C, 57.15; H, 4.45; N, 25.54. 
 
4.6.4. 7-Chloro-3-isobutyl-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (5d) 
Colorless needles; yield 0.81 g (2.82 mmol, 94%); mp 107–108 °C (n-octane); Rf 0.55 (n-hexane/EtOAc, 5:1); IR 
(Nujol): 1590, 1560, 1465, 1400, 1155, 710 cm–1; 1H NMR (CDCl3): δ 1.04 (d, J=6.6 Hz, 6H, 2×CH3), 2.47–2.61 (m, 
1H, N-CH2CH), 4.58 (d, J=7.2 Hz, 2H, N-CH2), 7.49–7.56 (m, 3H, Ph-m,pH), 8.56 (dd, Jo,p=2.1 Hz, Jo,m=7.5 Hz, 2H, 
Ph-oH); UV (EtOH): λmax (log ε) 247 (4.62), 253 (4.61), 265 (4.42), 272 (4.40), 289 (4.39), 303 nm (4.42); Anal. Calcd 
for C14H14ClN5: C, 58.44; H, 4.90; N, 24.34. Found: C, 58.29; H, 4.91; N, 24.09. 
 
4.7. General procedure (C) for the synthesis of 4a-d from 5a–d  
Sodium (0.05 g, 2.17 mmol) was dissolved in absolute methanol (30 mL) and to it was added an appropriate 5a–d 
(1.0 mmol). The resulting solution was stirred at rt for 1–2 h. Then, the solution was evaporated in vacuo to dryness and 
water (10 mL) was added to the residue. Thus, the solid deposited was filtered, washed with water, and recrystallized 
from a mixture of n-octane and EtOAc to afford the corresponding products 4a–d in 91%, 94%, 93% and 87% yields, 
respectively. 
 
4.8. 7-Chloro-3-(2-chloroethyl)-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (6) 
The compound 6 was prepared from 2f (0.50 g, 1.94 mmol) according to the general procedure for chlorination of 
2a–d as pale yellow needles; yield 0.50 g (87%); mp 129–130 °C (n-octane/EtOAc); Rf 0.22 (n-hexane/EtOAc, 5:1); IR 
(Nujol): 1590, 1555, 1460, 1160, 710 cm–1; 1H NMR (CDCl3): δ 4.17 (t, J=6.3 Hz, 2H, Cl-CH2), 5.09 (t, J=6.3 Hz, 2H, 
N-CH2), 7.51–7.58 (m, 3H, Ph-m,pH), 8.56 (dd, Jo,p=2.1 Hz, Jo,m=7.8 Hz, 2H, Ph-oH); UV (EtOH): λmax (log ε) 246 
(4.67), 252 (4.66), 265 (4.45), 273 (4.43), 290 (4.45), 302 nm (4.48); Anal. Calcd for C12H9Cl2N5: C, 49.00; H, 3.08; N, 
23.81. Found: C, 48.90; H, 3.35; N, 23.57.  
 
4.9. 7-Chloro-3-(3-chloropropyl)-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (7) 
The compound 7 was prepared from 2g (0.60 g, 2.21 mmol) in the similar way to 6 as colorless prisms; yield 0.57 g 
(84%); mp 120–121 °C (n-hexane); Rf 0.30 (n-hexane/EtOAc, 5:1); IR (Nujol): 1590, 1560, 1460, 1160, 710 cm–1; 1H 
NMR (CDCl3): δ 2.60 (quin, J=6.3 Hz, 2H, N-CH2CH2), 3.65 (t, J=6.3 Hz, 2H, Cl-CH2), 4.96 (t, J=6.6 Hz, 2H, N-CH2), 
7.51–7.56 (m, 3H, Ph-m,pH), 8.57 (dd, Jo,p=2.4 Hz, Jo,m=7.8 Hz, 2H, Ph-oH); UV (EtOH): λmax (log ε) 247 (4.53), 252 
(4.53), 264 (4.37), 272 (4.38), 290 (4.31), 303 nm (4.33); Anal. Calcd for C13H11Cl2N5: C, 50.67; H, 3.60; N, 22.73. 
Found: C, 51.00; H, 3.74; N, 22.54. 
 
4.10. 3-(2-Chloroethyl)-7-methoxy-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (8) 
To a solution of sodium methoxide (from 0.03 g of Na, 1.30 mmol) in methanol (25 mL) was added 6 (0.15 g, 0.51 
mmol) and the mixture was stirred at rt for 1 h. Then, the solvent was removed in vacuo and water (10 mL) was added 
to the residue. Thus, the solid deposited was collected by filtration, washed with water to give the product 8 as pale 
yellow needles; yield 0.12 g (81%); mp 182–183 °C (n-octane/EtOAc); Rf 0.16 (n-hexane/EtOAc, 5:1); IR (nujol): 1245, 
1085 (C-O-C) cm–1; 1H NMR (CDCl3): δ 4.15 (t, J=6.3 Hz, 2H, Cl-CH2), 4.38 (s, 3H, O-CH3), 5.03 (t, J=6.3 Hz, 2H, 
N-CH2), 7.49–7.53 (m, 3H, Ph-m,pH), 8.56 (dd, Jo,p=1.8 Hz, Jo,m=7.8 Hz, 2H, Ph-oH); UV (EtOH): λmax (log ε) 237 
(4.54), 244 (4.49), 276 (4.48), 284 (4.50), 292 (4.47), 304 nm (4.23); Anal. Calcd for C13H12ClN5O: C, 53.89; H, 4.17; 
N, 24.17. Found: C, 53.84; H, 4.22; N, 24.10.  
 
4.11. 3-(3-Chloropropyl)-7-methoxy-5-phenyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (9) 
The compound 9 was prepared from 7 (0.15 g, 0.49 mmol) in an analogous way to 8 as colorless needles; yield 0.13 
g (88%); mp 115–116 °C (n-octane/EtOAc); Rf 0.18 (n-hexane/EtOAc, 5:1); IR (Nujol): 1250, 1085 (C-O-C) cm–1; 1H 
NMR (CDCl3): δ 2.58 (quin, J=6.3 Hz, 2H, N-CH2CH2), 3.64 (t, J=6.3 Hz, 2H, Cl-CH2), 4.38 (s, 3H, O-CH3), 4.90 (t, 
J=6.6 Hz, 2H, N-CH2), 7.50–7.53 (m, 3H, Ph-m,pH), 8.56 (dd, Jo,p=1.8 Hz, Jo,m=8.1 Hz, 2H, Ph-oH); UV (EtOH): λ
max (log ε) 238 (4.63), 245 (4.59), 276 (4.59), 285 (4.62), 292 (4.60), 304 nm (4.35); Anal. Calcd for C14H14ClN5O: C, 
55.36; H, 4.65; N, 23.06. Found: C, 55.27; H, 4.63; N, 22.91. 
 
4.12. Methylation of 2b with dimethyl sulfate 
4.12.1. At room temperature 
A mixture of 2b (0.5 g, 1.96 mmol), anhydrous K2CO3 (0.54 g, 3.92 mmol), and dimethyl sulfate (0.37 g, 2.94 
mmol) in dry DMF (25 mL) was stirred at rt for 8 h. After the usual work-up like the general method as described in 
Section 4.4.1., the compounds 3b and 4b were obtained in 17% and 61% yields, respectively. 
 
4.12.2. At boiling temperature 
The above methylation of 2b with dimethyl sulfate at boiling temperature for 3 h gave 3b and 4b in 16% and 39% 
yields, respectively. 
 
4.13. Ethylation of 2b with ethyl iodide 
4.13.1. At room temperature 
A mixture of 2b (0.62 g, 2.43 mmol), anhydrous K2CO3 (0.67 g, 4.86 mmol), and ethyl iodide (1.04 g, 7.3 mmol) in 
dry DMF (25 mL) was stirred at rt for 8 h. Then, the solution was evaporated to dryness in vacuo and water (20 mL) 
was added to the residue. The solid deposited was collected by filtration and washed with water. The two regioisomers 
cropped were separated by column chromatography using n-hexane/EtOAc (6:1→1:1) as eluting solvent to afford the 
7-O-ethyl 4ba and 6-N-ethyl derivatives 3ba as the first and second fraction, respectively. 
 
4.13.1.1. 6-Ethyl-5-phenyl-3-propyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one (3ba) 
Pale yellow needles; yield 0.07 g (10%); mp 145–146 °C (n-hexane/EtOAc); Rf 0.48 (n-hexane/EtOAc, 1:2); IR 
(Nujol): 1710 (CO) cm–1; 1H NMR (CDCl3): δ 0.98 (t, J=7.5 Hz, 3H, 3-CH2CH2CH3), 1.22 (t, J=7.2 Hz, 3H, 
6-CH2CH3), 2.03 (sext, J=7.5 Hz, 2H, 3-CH2CH2), 4.08 (q, J=7.2 Hz, 2H, 6-CH2), 4.49 (t, J=7.2 Hz, 2H, 3-CH2), 
7.48–7.59 (m, 5H, Ph-H); UV (EtOH): λmax (log ε) 265 (4.33), 272 nm (4.30 ); Anal. Calcd for C15H17N5O: C 63.59, H 
6.05, N 24.72. Found: C 63.89, H 6.17, N 24.58. 
 
4.13.1.2. 7-Ethoxy-5-phenyl-3-propyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (4ba) 
Colorless needles; yield 0.45 g (66%); mp 73–74 °C (n-octane/EtOAc); Rf 0.40 (n-hexane/EtOAc, 5:1); IR (Nujol): 
1245, 1085 (C-O-C) cm–1; 1H NMR (CDCl3): δ 1.01 (t, J=7.2 Hz, 3H, 3-N-CH2CH2CH3), 1.61 (t, J=7.2 Hz, 3H, 
O-CH2CH3), 2.13 (sext, J=7.2 Hz, 2H, N-CH2CH2), 4.67 (t, J=7.2 Hz, 2H, N-CH2), 4.87 (q, J=7.2 Hz, 2H, O-CH2), 
7.48–7.54 (m, 3H, Ph-m,pH), 8.54 (dd, Jo,p=2.1 Hz, Jo,m=7.5 Hz, 2H, Ph-oH); UV (EtOH): λmax (log ε) 239 (4.48), 246 
(4.45), 277 (4.44), 285 (4.45), 292 (4.42), 304 nm (4.15); Anal. Calcd for C15H17N5O: C 63.59, H 6.05, N 24.72. Found: 
C 63.49, H 6.10, N 24.67. 
 
4.13.2. At boiling temperature 
The above ethylation of 2b with little more excess ethyl iodide (ca. 5 equiv) at boiling temperature for 4 h gave 3ba 
and 4ba in 18% and 41% yields, respectively. 
 
4.14. Preparation of 4ba from 5b 
To a solution of sodium ethoxide (from 0.02 g of Na, 0.87 mmol) in absolute ethanol (20 mL) was added 5b (0.11 g, 
0.40 mmol) and the solution was stirred at rt for 1 h. The solvent was removed in vacuo and water (10 mL) was added 
to the residue. Thus, the solid deposited was collected by filtration, washed with water to give 4ba (0.09 g, 79%), which 
was identical in all respects with authentic sample prepared by another method. 
 
4.15. Benzylation of 2b with benzyl bromide 
 
4.15.1. At room temperature 
A mixture of 2b (0.55 g, 2.16 mmol), anhydrous K2CO3 (0.60 g, 4.32 mmol) and benzyl bromide (0.55 g, 3.24 
mmol) in dry DMF (25 mL) was stirred at rt for 8 h. Then, the solution was evaporated to dryness in vacuo and water 
(20 mL) was added to the residue. The solid deposited was collected by filtration and washed with water. The two 
regioisomers cropped were separated by column chromatography using n-hexane/EtOAc (6:1→1:1) as eluting solvent 
to afford the 7-O-benzyl 4bb and 6-N-benzyl derivatives 3bb as the first and second fraction, respectively. 
 
4.15.1.1. 6-Benzyl-5-phenyl-3-propyl-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7(6H)-one (3bb) 
Colorless needles; yield 0.10 g (13%); mp 156–157 °C (n-hexane/EtOAc); Rf 0.55 (n-hexane/EtOAc, 1:2); IR 
(Nujol): 1715 (CO) cm–1; 1H NMR (CDCl3): δ 0.99 (t, J=7.5 Hz, 3H, CH3), 2.04 (sext, J=7.5 Hz, 2H, N-CH2CH2), 4.50 
(t, J=7.5 Hz, 2H, N-CH2), 5.30 (s, 2H, CH2Ph), 6.84–6.88 (m, 2H, Ph-H), 7.17–7.27 (m, 5H, Ph-H), 7.42 (t, J=7.8 Hz, 
2H, Ph-H), 7.49–7.55 (m, 1H, Ph-H); UV (EtOH): λmax (log ε) 265 (4.36), 272 nm (4.33); Anal. Calcd for C20H19N5O: C 
69.55, H 5.54, N 20.28. Found: C 69.73, H 5.65, N 20.06. 
 
4.15.1.2. 7-Benzyloxy-5-phenyl-3-propyl-3H-[1,2,3]triazolo[4,5-d]pyrimidine (4bb) 
Colorless needles; yield 0.47 g (63%); mp 105–106 °C (n-octane/EtOAc); Rf 0.40 (n-hexane/EtOAc, 5:1); IR 
(Nujol): 1250 (C-O-C) cm–1; 1H NMR (CDCl3): δ 1.02 (t, J=7.5 Hz, 3H, CH3), 2.12 (sext, J=7.2 Hz, 2H, N-CH2CH2), 
4.67 (t, J=7.2 Hz, 2H, N-CH2), 5.86 (s, 2H, CH2Ph), 7.34–7.43 (m, 3H, Ph-H), 7.50–7.53 (m, 3H, Ph-H), 7.61 (d, J=7.2 
Hz, 2H, Ph-H), 7.55 (dd, J=2.1 Hz, J=7.5 Hz, 2H, Ph-H); UV (EtOH): λmax (log ε) 240 (4.60), 247 (4.57), 276 (4.51), 
284 (4.53), 293 (4.49), 304 nm (4.26); Anal. Calcd for C20H19N5O: C 69.55, H 5.54, N 20.28. Found: C 69.59, H 5.63, 
N 20.12. 
 
4.15.2. At boiling temperature 
The above benzylation of 2b with benzyl bromide at boiling temperature for 1 h gave 3bb and 4bb in 37% and 35% 
yields, respectively. 
 
4.16. Preparation of 2-phenyl-9-propyl-9H-purin-6(1H)-one (10) 
A solution of free 5,6-diaminopyrimidine derivative 1b (1.0 g, 4.09 mmol) in 85% aqueous formic acid (15 mL) 
was heated under reflux for overnight. Then, the solution was concentrated to ca. 2 mL and to it was added water (15 
mL). Thus, the solid deposited was collected by filtration and washed with water to afford 10 as pale yellow powdery 
crystals; yield 0.78 g (75%); mp 265–267 °C (EtOAc/EtOH); Rf 0.47 (EtOAc/EtOH, 4:1); IR (Nujol): 3175 (NH), 1690 
(CO) cm–1; 1H NMR (CDCl3): δ 1.0 (t, J=7.5 Hz, 3H, CH3), 1.98 (sext, J=7.4 Hz, 2H, N-CH2CH2), 4.21 (t, J=7.4 Hz, 
2H, N-CH2), 7.52–7.62 (m, 3H, Ph-m,pH), 7.81 (s, 1H, N=CH), 8.22–8.25 (m, 2H, Ph-oH), 11.90 (s, 1H, NH); UV 
(EtOH): λmax (log ε) 261 (3.99), 302 nm (4.14); Anal. Calcd for C14H14N4O·1/8H2O: C 65.55, H 5.60, N 21.84. Found: 
C 65.49, H 5.64, N 21.89. 
 
4.17. Methylation of 10 
 
4.17.1. With 1 equiv MeI at 0 °C 
A mixture of 10 (0.4 g, 1.57 mmol), anhydrous K2CO3 (0.4 g, 2.89 mmol), and MeI (0.23 g, 1.62 mmol) in dry 
DMF (20 mL) was stirred at 0 °C for 1.5 days. Then, the solution was evaporated to dryness in vacuo and water (10 
mL) was added to the residue. The products were extracted with CH2Cl2 and the extract was dried over anhydrous 
MgSO4. Solvent was removed in vacuo and the residue was subjected to column chromatography on silica gel column 
using n-hexane/EtOAc (2:1→1:10) as eluting solvent to give 11b and 11a as the first and second fractions, respectively.  
 
4.17.1.1. 1-Methyl-2-phenyl-9-propyl-9H-purin-6(1H)-one (11a) 
Colorless needles; yield 0.11 g (26%); mp 169–170 °C (n-hexane/EtOAc); Rf 0.53 (EtOAc/EtOH, 4:1); IR (Nujol): 
1685 (CO) cm–1; 1H NMR (CDCl3): δ 0.96 (t, J=7.5 Hz, 3H, CH2CH3), 1.90 (sext, J=7.4 Hz, 2H, N-CH2CH2), 3.53 (s, 
3H, N-CH3), 4.12 (t, J=7.4 Hz, 2H, N-CH2), 7.53 (s, 5H, Ph-H), 7.77 (s, 1H, N=CH); UV (EtOH): λmax (log ε) 254 
(4.02), 282 nm (4.01); Anal. Calcd for C15H16N4O: C 67.15, H 6.01, N 20.88. Found: C 67.29, H 6.11, N 20.77. 
 
4.17.1.2. 6-Methoxy-2-phenyl-9-propyl-9H-purine (11b) 
Pale yellow powdery crystals; yield 0.19 g (45%); mp 115 °C (n-hexane/EtOAc); Rf 0.22 (n-hexane/EtOAc, 1:1); IR 
(Nujol): 1240, 1080 (C-O-C) cm–1; 1H NMR (CDCl3): δ 1.0 (t, J=7.5 Hz, 3H, CH2CH3), 2.01 (sext, J=7.4 Hz, 2H, 
N-CH2CH2), 4.26 (t, J=7.4 Hz, 2H, N-CH2), 4.29 (s, 3H, O-CH3), 7.43–7.52 (m, 3H, Ph-m,pH), 7.89 (s, 1H, N=CH), 
8.53 (dd, Jo,p=2.1 Hz, Jo,m=7.8 Hz, 2H, Ph-oH); UV (EtOH): λmax (log ε) 231 (4.30), 237 (4.28), 282 (4.37), 290 (4.34), 
305 nm (3.97); Anal. Calcd for C15H16N4O: C 67.15, H 6.01, N 20.88. Found: C 66.93, H 6.12, N 20.80.  
 
4.17.2. With 1 equiv Me2SO4 at room temperature 
A mixture of 10 (0.3 g, 1.18 mmol), anhydrous K2CO3 (0.3 g, 2.17 mmol), and Me2SO4 (2.3 g, 1.62 mmol) in dry 
DMF (20 mL) was stirred at rt for 1 day. Then, the solution was evaporated to dryness in vacuo and water (10 mL) was 
added to the residue. The products were extracted with CH2Cl2 and the extract was dried over anhydrous MgSO4. 
Solvent was removed in vacuo and the residue was recrystallized from n-hexane to give 11b (0.24 g, 76%). 
 
4.17.3. With excess MeI at room temperature 
A mixture of 10 (0.4 g, 1.57 mmol), anhydrous K2CO3 (0.45 g, 3.26 mmol), and MeI (0.60 g, 4.23 mmol) in DMF 
(20 mL) was stirred at rt for 15 h. Then, another portion of MeI (0.50 g, 3.52 mmol) was added to the reaction mixture 
and the mixture was stirred at rt for additional 15 h. The usual work-up like method as descryibed in Section 4.17.1 
gave 12 and 11b as the first and second fractions in 30% and 44% yields, respectively. 
 
4.17.3.1. 6,9-Dihydro-1,7-dimethyl-6-oxo-2-phenyl-9-propyl-1H-purin-7-ium hydroxide (12) 
Colorless prisms; mp 147 °C (n-hexane); Rf 0.48 (n-hexane/EtOAc, 1:1); IR (Nujol): 3350 (OH), 1680 (CO) cm–1; 
1H NMR (CDCl3): δ 0.99 (t, J=7.5 Hz, 3H, CH2CH3), 1.68 (sext, J=7.4 Hz, 2H, N-CH2CH2), 3.08 (s, 3H, 1-N-CH3), 
3.54–3.61 (m, 2H, N-CH2), 4.04 (s, 3H, 7-N-CH3), 4.95 (br s, 1H, OH), 7.43–7.48 (m, 3H, Ph-m,pH), 8.0 (s, 1H, 
N=CH), 8.43 (dd, Jo,p=2.1 Hz, Jo,m=7.5 Hz, 2H, Ph-oH); UV (EtOH): λmax (log ε) 240 (4.67), 246 (4.69), 262 (4.40), 299 
(4.02); Anal. Calcd for C16H20N4O2: C 63.98, H 6.71, N 18.65. Found: C 63.59, H 6.65, N 18.61. 
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